Dominant-negative ATF5 rapidly depletes survivin in tumor cells

Survivin (BIRC5, product of the BIRC5 gene) is highly expressed in many tumor types and has been widely identified as a potential target for cancer therapy. However, effective anti-survivin drugs remain to be developed. Here we report that both vector-delivered and cell-penetrating dominant-negative...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xiaotian, Angelastro, James M., Merino, David, Zhou, Qing, Siegelin, Markus D., Greene, Lloyd A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760124/
https://www.ncbi.nlm.nih.gov/pubmed/31551409
http://dx.doi.org/10.1038/s41419-019-1872-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760124/
https://www.ncbi.nlm.nih.gov/pubmed/31551409
http://dx.doi.org/10.1038/s41419-019-1872-y

Ejemplares similares